This launch is part of the company's strategy to expand its nutraceutical portfolio
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
Subscribe To Our Newsletter & Stay Updated